Arena Pharmaceuticals Awaits FDA Advisory Committee Meeting
(firmenpresse) - LOS ANGELES, CALIFORNIA -- (Marketwire) -- 05/07/12 -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) is awaiting its opportunity to readdress the U.S. Federal Food and Drug Administration's Advisory Committee, as it continues to seek approval for its weight-loss drug Locaserin. The meeting is scheduled for May 10, 2012. This will be the second attempt by Arena to gain the favor of the committee, after it submitted additional results in response to concerns expressed by the FDA, within its previous Complete Response Letter and with respect to the company's previous New Drug Application. The company is currently in a race with Vivus, Inc. and Orexigen Therapeutics, Inc, to bring the first weight-loss drug to market in over a decade.
Legitimate Investor reviews the likelihood of Arena being successful in its application, in a new report which can be accessed at:
Legitimate Investor provides Market Research, Analysis and Opinions focused on equities that are in the forefront of the investing public. Legitimate Investor has not been compensated by any of the above-mentioned companies. We act as an independent research portal and caution that all investment entails inherent risks. Please view the full disclaimer at:
Contacts:
Legitimate Market, Inc.
Market Research
250-448-1807
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 07.05.2012 - 16:47 Uhr
Sprache: Deutsch
News-ID 143428
Anzahl Zeichen: 0
contact information:
Town:
LOS ANGELES, CALIFORNIA
Kategorie:
Drugs
Diese Pressemitteilung wurde bisher 202 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Arena Pharmaceuticals Awaits FDA Advisory Committee Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
Arena Pharmaceuticals, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
